2024-12-13 00:58:49
Latest Post
Premium Lingerie Brand MHYTH Raises Angel Funding, achieves Over $1M Valuation Within a month of launch
Sodhani Academy of Fintech Enablers Ltd enters into agreement with BFSI SSC
Ashok Leyland Ltd receives order for 1475 BSVI Diesel Passenger Bus Chassis from TNSTC
Operations of MDF plant at Greenply Speciality Panels Pvt Ltd suspended due to machinery breakdown
GHCL got Environment Clearance for Soda Ash Greenfield Plant
Stock Report
Alembic Pharmaceuticals Ltd Q2 FY25 consolidated net profit at Rs. 153.41 crores
Posted On : 2024-11-07 21:27:17( TIMEZONE : IST )
Alembic Pharmaceuticals Limited has reported Consolidated financial results for the period ended September 30, 2024.
Financial Results (Q2 FY2025) - QoQ Comparison
The company has reported total income of Rs. 1664.72 crores during the period ended September 30, 2024 as compared to Rs. 1563.83 crores during the period ended June 30, 2024.
The company has posted net profit / (loss) of Rs. 153.41 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs. 134.71 crores for the period ended June 30, 2024.
The company has reported EPS of Rs. 7.79 for the period ended September 30, 2024 as compared to Rs. 6.84 for the period ended June 30, 2024.
| Financials | Q2 FY2025 | Q1 FY2025 | % Change |
| Total Income | ₹ 1664.72 crs | ₹1563.83 crs |  6.45% |
| Net Profit | ₹153.41 crs | ₹134.71 crs | 13.88% |
| EPS | ₹7.79 | ₹6.84 | 13.89% |
Financial Results (Q2 FY2025) - YoY Comparison
The company has reported total income of Rs. 1664.72 crores during the period ended September 30, 2024 as compared to Rs.1605.08 crores during the period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.153.41 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs.136.56 crores for the period ended September 30, 2023.
The company has reported EPS of Rs.7.79 for the period ended September 30, 2024 as compared to Rs.6.95 for the period ended September 30, 2023.
| Financials | Q2 FY2025 | Q2 FY2024 | % Change |
| Total Income | ₹ 1664.72 crs | ₹1605.08 crs | 3.72% |
| Net Profit | ₹153.41 crs | ₹136.56 crs | 12.34% |
| EPS | ₹7.79 | ₹6.95 | 12.09% |
Financial Results (Half Year Ended FY2025) - YoY Comparison
The company has reported total income of Rs.3228.55 crores during the 6 Months period ended September 30, 2024 as compared to Rs.3102.90 crores during the 6 Months period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.288.12 crores for the 6 Months period ended September 30, 2024 as against net profit / (loss) of Rs.257.16 crores for the 6 Months period ended September 30, 2023.
The company has reported EPS of Rs.14.64 for the 6 Months period ended September 30, 2024 as compared to Rs.13.08 for the 6 Months period ended September 30, 2023.
| Financials | Half Year Ended FY2025 | Half Year Ended FY2024 | % Change |
| Total Income | ₹3228.55 crs | ₹3102.90 crs | 4.05% |
| Net Profit | ₹288.12 crs | ₹257.16 crs | 12.04% |
| EPS | ₹14.64 | ₹13.08 | 11.93% |
Shares of Alembic Pharmaceuticals Limited was last trading in BSE at Rs. 1081.45 as compared to the previous close of Rs. 1139.20. The total number of shares traded during the day was 13084 in over 1414 trades.
The stock hit an intraday high of Rs. 1152.60 and intraday low of 1072.60. The net turnover during the day was Rs. 14470168.00.
